BioSpace News Archive

BioMidwest

New ID NOW Data Released by Abbott Refutes Negative New York Study Results

Abbott released a positive interim analysis of an ongoing clinical study assessing the accuracy of its ID NOW COVID-19 rapid that showed the test that can provide results within 15 minutes has a high degree of specificity and sensitivity.

May 22, 2020
·
2 min read
·
Alex Keown
BioForest

Clinical Catch-Up: May 18-22

Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.

May 22, 2020
·
9 min read
·
Mark Terry
Drug Development

CanSino Publishes Phase I Data for COVID-19 Vaccine Candidate, Moves into Phase II

A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.

May 22, 2020
·
2 min read
·
Alex Keown
Drug Development

Biotech Bay Companies Fighting Against COVID-19

Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

May 22, 2020
·
11 min read
·
Chelsea Weidman Burke, M.S.
Business

Mammoth’s GSK Collaboration Aims to End Dichotomy Between Lab and Home Dx Tests, CEO Says

The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.

May 22, 2020
·
4 min read
·
Gail Dutton
Deals

Following Failure to Sell, Akorn Files for Chapter 11

Two years after Germany’s Fresenius Medical Care walked away from a 2017 $4.3 billion deal to acquire Akorn Pharmaceuticals, the company has filed for protection under U.S. bankruptcy laws as it attempts to restructure for a potential sale.

May 22, 2020
·
2 min read
·
Alex Keown
Business

Large International Study of Chloroquine for COVID-19 Shows No Benefit and Significant Harm

The study found that of the 15,000 patients who received either of the drugs were almost twice as likely to die compared to the patients who did not receive them. The research was published in the journal The Lancet.

May 22, 2020
·
3 min read
·
Mark Terry
Business

Hot, Humid Weather Slows SARS-CoV-2 Transmission, but Won’t End the Crisis

A hot, humid summer will slow coronavirus transmission but, on its own isn’t likely to end the COVID-19 pandemic, according to a new study.

May 22, 2020
·
4 min read
·
Gail Dutton
Policy

Biopharma Update on the Novel Coronavirus: May 22

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.

May 22, 2020
·
4 min read
·
BioSpace Editorial Staff
Policy

FDA Action Alert: Evofem, Sanofi, Regeneron and Incyte

Heading into the first week after Memorial Day, which in the U.S. marks the typical beginning of summer, the U.S. Food and Drug Administration has a number of drug approvals on the calendar. Here’s a look.

May 22, 2020
·
3 min read
·
Mark Terry